TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

TScan's multiplexed TCR-T targeting both Mage and Prame simultaneously appears well thought out / researched. ( Nice presentations and slides).

Targeting the heterogeneity aspects ( for me i think of that as cancer dark matter) means thinking ahead to the mutations and stopping the cancer metastasis.

BMS is in deep over at IMTX, if i recall correctly Novartis deal with TCRX expires soon, if results come in decent i could see BMS interested here, imo.

TCRX is hard to read stock wise, undervalued imo, results at ASH might attract more respect.

TCRX management - upper echelon, imo.